The High-Dose Aldesleukin (IL-2) “Select” Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High-Dose IL-2 Treatment in Patients With Metastatic Renal Cell Carcinoma

Autor: Clement, Jessica M., McDermott, David F.
Zdroj: In Clinical Genitourinary Cancer 2009 7(2):E7-E9
Databáze: ScienceDirect
Externí odkaz: